Professor Richard Scolyer AO


Co-Medical Director

Professor Richard Scolyer is Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; Co- Medical Director, Melanoma Institute Australia; and Conjoint Professor, Central Clinical School, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney.

He provides a clinical consultation service for the diagnosis of difficult pigmented lesions and receives more than 2000 cases for opinion from Australasia and beyond annually. Richard effectively integrates his clinical practice with leading an award winning translational melanoma research laboratory.

His record includes co-authoring more than 700 peer reviewed publications/book-chapters including in prestigious journals such as New England Journal of Medicine, Lancet, Nature, Cell, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer Discovery with >43,000 citations and a h-index of 105 (Google Scholar as at 17.12.2020). Richard has presented on more than 370 occasions at conferences throughout the world.

In June 2021 Professor Scolyer was appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly in the field of melanoma and skin cancer, as a clinician, researcher and educator, and to national and international professional organisations.

In 2020 he received the Cancer Institute NSW Premier's Award – Outstanding Cancer Researcher of the Year, the Royal College of Pathologists of Australasia (RCPA) Distinguished Fellow Award 2020, The University of Sydney’s 2020 Alumni Award for International Achievement and Clarivate Web of Science Group “Highly Cited Researcher 2020”. He has received the NSW Premier's Award for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017 and 2018, Thomson Reuters 2015 Citation Award in the Clinical Medicine category, the 2018 William O. Russell/Joanne Vandenberge Hill Award for Lifetime Achievement in Anatomical Pathology, MD Anderson Cancer Center, Research Australia’s 2018 GSK Award for Research Excellence, the 2019 American Society of Dermatopathology’s Elson B Helwig Award for excellence in dermatopathology. His publications have received most highly cited awards on 5 other occasions. Recently, Richard was recognised as a Clarivate Web of Science “Highly Cited Researcher 2019” and again in 2020. According to Thomson Reuters ISI Web of Knowledge, Richard is the highest ever published scientist in the world in the field of melanoma pathology and he also has the highest H index in this field. The Fame Report (2011) published by Medical Experts International ( ranked him the 6th leading melanoma expert in any field or discipline worldwide and the highest ranked melanoma pathologist worldwide. In September 2020, he was ranked the world’s 7th leading melanoma expert in any field or discipline and the world’s leading melanoma pathologist ( In September 2020, Richard was ranked as the leading Australian Pathologist in the entire field of Pathology (

Richard was an editor of the 4th Edition of the World Health Organisation Classification of Tumours (Skin Tumours volume) in which he was the responsible editor for 3 of the 6 sections and authored/co-authored more than 30 chapters. He has also been an invited contributing author to 6 other volumes of the WHO Classification of Tumours including for Soft Tissue and Bone, Digestive System, Thoracic, Female Genital Tract and Paediatric tumours.

He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of AJCC Cancer Staging System, co-leads the Australian Melanoma Genome Project (part of the International Cancer Genome Consortium), was lead pathologist for the NIH funded The Cancer Genome Atlas (TCGA) Melanoma Project (Cell, 2015), chairs the Melanoma Expert Panel for the International Collaboration on Cancer Reporting, and lead pathologist/member of the overseeing Management Committee, Multidisciplinary Working Party and Author for the Australian Melanoma Clinical Practice Guidelines and co-lead author of the College of American Pathologists Melanoma Reporting protocol. He is also an editorial board member of the American Journal of Surgical Pathology, Modern Pathology and Histopathology and several other international journals and Senior Associate Editor of Pathology. Richard is a Past President of the Australasian Division of the International Academy of Pathology and is the current International Vice President representing Australasian on the International Academy of Pathology International Council. In 2019, Richard was the RCPA visiting Professor/Lecturer to Asia. Together with his MIA colleagues, Richard has been chief investigator on 3 consecutive 5 year NHMRC program grants and has received multiple personal Fellowships from the NHMRC and CINSW. He has also been an investigator/advisor on multiple phase 1, 2 and 3 clinical trials and a frequently sought-after advisor to industry.

Professor Scolyer studied medicine at the University of Tasmania. After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. In 2006, Professor Scolyer was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology.

To get in touch with Professor Richard Scolyer, please email Kara Taylor, Executive Assistant at

Prof Scolyer Recent News

Prof Scolyer Recent Publications

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

2022-06-07T16:35:14+10:00April 30th, 2022|

Jason J Luke, Prof Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Prof Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Prof Muhammad A Khattak, Prof Dirk Schadendorf, Prof Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Prof Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Prof Vernon K Sondak, Prof Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Prof Alexander M M. Lancet. (30 Apr 2022)


Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

2022-06-09T10:58:09+10:00February 9th, 2021|

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long.  Nat Med (2021).


Go to Top